Study guide

4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways

Key Takeaways Explain This Topic AI

Lipinski's Rule of Five (MW <= 500, logP <= 5, H-bond donors <= 5, H-bond acceptors <= 10) predicts oral drug-likeness for passively absorbed molecules.

Henderson-Hasselbalch governs ionization: weak acids are unionized (and absorbed) in the stomach, weak bases are unionized (and absorbed) in the intestine.

logP measures lipophilicity of the unionized form; logD at pH 7.4 better predicts in vivo distribution because it accounts for ionization.

Phase I metabolism (mainly CYP450) introduces or unmasks polar groups via oxidation, reduction, or hydrolysis; CYP3A4 metabolizes about half of all drugs.

Phase II metabolism conjugates a polar endogenous group (glucuronide, sulfate, acetate, glutathione, methyl, or amino acid) to produce water-soluble metabolites for excretion.

Last updated: July 2026

4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways

Quick Answer: A drug's physicochemical signature (molecular weight, lipophilicity, ionization, solubility, protein binding) dictates its ADME fate. The CYP450 enzyme family drives Phase I oxidation; conjugation reactions drive Phase II. Master these to predict bioavailability, drug interactions, and patient variability.

Medicinal chemistry explains why a molecule behaves in the body the way it does. The FPGEE frequently tests physicochemical relationships and metabolism pathways because they form the mechanistic basis for pharmacokinetics, drug interactions, and individual variability.

Lipinski's Rule of Five

Pfizer's Christopher Lipinski proposed a heuristic for drug-likeness - the likelihood that a small molecule is orally bioavailable via passive absorption:

  • Parameter Threshold
  • Molecular weight <= 500 Da
  • logP (lipophilicity) <= 5
  • H-bond donors <= 5
  • H-bond acceptors <= 10

Two or more violations suggest poor oral absorption. The rule applies only to passively absorbed molecules; substrates of active transporters (e.g., some antibiotics, oncologics, peptides) routinely violate it and still absorb well.

Ionization and Absorption

The Henderson-Hasselbalch equation governs the unionized fraction that crosses lipid membranes by passive diffusion. Unionized drug is lipophilic and crosses; ionized drug is hydrophilic and remains in the lumen.

  • Drug type Predominant site of absorption Why
  • Weak acid (pKa 3 to 5) Stomach (pH 1 to 3) Mostly unionized at low pH
  • Weak base (pKa 8 to 10) Intestine (pH 5 to 7) Mostly unionized at higher pH

Very weak acids (pKa > 7) or very weak bases (pKa < 5) are largely unionized throughout the GI tract and are absorbed everywhere.

Lipophilicity: logP and logD

logP = partition coefficient (octanol/water) for the unionized form of a molecule.

logD = distribution coefficient at a stated pH, accounting for ionization.

The optimal logP for oral drugs is typically 1 to 3. Higher logP increases membrane permeability but reduces aqueous solubility, raises metabolism, and increases protein binding. Lower logP impairs permeability. logD at pH 7.4 is the best single predictor of in vivo distribution behavior.

Solubility and Solid-State Properties

Polymorphism : the same molecule can crystallize in different packing arrangements. Polymorphs differ in solubility, dissolution rate, and bioavailability - the classic case is the ritonavir polymorph II crisis of 1998 , which forced a market withdrawal.

Amorphous vs crystalline : amorphous forms have higher free energy, dissolve faster, but are physically less stable.

Hydrates : water molecules occupy specific positions in the crystal lattice; hydrates are usually less soluble than the corresponding anhydrate.

Cosolvents : ethanol, propylene glycol, glycerin, and polyethylene glycol increase the solubility of poorly water-soluble drugs in parenteral formulations.

Protein Binding

  • Protein Binds Clinical effect
  • Albumin Acidic and neutral drugs High binding means low free fraction; displacement raises free drug
  • alpha-1-acid glycoprotein (AAG) Basic drugs Inflammation raises AAG, increasing binding of basic drugs

Only free drug is pharmacologically active , distributes into tissues, is metabolized, and is cleared. Total drug concentration assays can mislead in hypoalbuminemia (e.g., phenytoin in ICU patients) because the free fraction rises even when the total concentration looks therapeutic.

ADME Transport Mechanisms

Passive diffusion : down a concentration gradient; driven by lipophilicity (logD).

Facilitated or active transport : protein-mediated; saturable; can move against a gradient. Examples: OATP, P-glycoprotein (P-gp), OCT.

Paracellular transport : between cells; size-limited; minor in GI epithelium.

Endocytosis : large molecules such as proteins and some biologics.

Drug Metabolism

Metabolism converts lipophilic parent drugs into more polar, excretable metabolites. Two phases are conventionally distinguished.

Phase I - Functionalization

Reactions: oxidation, reduction, hydrolysis . Phase I introduces or unmasks a polar group (OH, NH2, SH, COOH) on the molecule. The reactions are primarily catalyzed by cytochrome P450 (CYP450) enzymes in the hepatic endoplasmic reticulum.

CYP Enzyme Share of drugs Representative substrates Strong inhibitors Strong inducers

CYP3A4 ~50% Midazolam, simvastatin, cyclosporine, many HIV ARVs Ketoconazole, clarithromycin, ritonavir, grapefruit Rifampin, carbamazepine, phenytoin, St. John's wort

CYP2D6 ~25% Codeine, metoprolol, fluoxetine, tamoxifen Fluoxetine, paroxetine, bupropion, quinidine None clinically significant

CYP2C9 ~10% Warfarin (S-enantiomer), NSAIDs, phenytoin, losartan Fluconazole, amiodarone, sulfamethoxazole Rifampin, carbamazepine

CYP1A2 ~5% Theophylline, caffeine, clozapine, tizanidine Ciprofloxacin, fluvoxamine, oral contraceptives Tobacco (PAHs), charbroiled meat, omeprazole

  • CYP2C19 ~5% Omeprazole, clopidogrel, diazepam Fluvoxamine, fluconazole, omeprazole Rifampin, carbamazepine
  • Phase II - Conjugation

Phase II attaches a polar endogenous group to the parent drug or Phase I metabolite: glucuronidation, sulfation, acetylation, glutathione conjugation, methylation, amino acid conjugation . Most Phase II metabolites are inactive and water-soluble, but notable exceptions include morphine-6-glucuronide (more active than morphine at the mu receptor) and N-acetylprocainamide (antiarrhythmic activity).

  • Reaction Enzyme system Example
  • Glucuronidation UGT (liver) Morphine to morphine-3-glucuronide and morphine-6-glucuronide
  • Sulfation SULT Steroids, acetaminophen
  • Acetylation NAT1 and NAT2 Isoniazid, hydralazine, procainamide
  • Glutathione conjugation GST Acetaminophen detoxification to mercapturic acid
  • Methylation COMT, TPMT Catecholamines, 6-mercaptopurine

Loading diagram... Drug Metabolism Pathway: Phase I to Phase II to Excretion

Metabolic Variations

Enzyme induction : increased enzyme synthesis speeds metabolism, lowers drug levels, and reduces effect. Classic inducers: rifampin, phenytoin, carbamazepine, St. John's wort, chronic alcohol, smoking (CYP1A2) .

Enzyme inhibition : competitive or mechanism-based inhibition slows metabolism and raises drug levels. Classic inhibitors: ketoconazole, ritonavir, erythromycin, clarithromycin, grapefruit juice, fluoxetine, ciprofloxacin, amiodarone .

Genetic polymorphisms matter clinically:

CYP2D6 poor metabolizers (5 to 10% of Caucasians) get no analgesia from codeine (cannot O-demethylate to morphine); ultra-rapid metabolizers risk fatal overdose from a normal codeine dose.

CYP2C19 poor metabolizers do not activate clopidogrel effectively, raising stent thrombosis risk; the FDA boxed warning addresses this.

NAT2 slow acetylators accumulate isoniazid, raising hepatotoxicity and lupus risk.

TPMT deficiency causes fatal myelosuppression from 6-mercaptopurine and 6-thioguanine; genotype before dosing.

First-pass effect : metabolism before the drug reaches systemic circulation, occurring in the gut wall, the liver (portal circulation), and (to a small extent) the lung. Sublingual, rectal (lower colon), and parenteral routes bypass hepatic first-pass metabolism.

Clinical Relevance on the FPGEE

The exam expects you to predict clinical consequences from physicochemical and metabolic facts:

Ketoconazole plus simvastatin raises simvastatin AUC roughly 20-fold via CYP3A4 inhibition, dramatically increasing rhabdomyolysis risk.

Rifampin plus oral contraceptives causes contraceptive failure via CYP3A4 induction (and possibly via P-gp induction).

Codeine in a CYP2D6 ultra-rapid metabolizer who is breastfeeding can cause fatal infant morphine exposure (FDA boxed warning).

Phenytoin in hypoalbuminemia has a higher free fraction at the same total concentration; the therapeutic range based on total concentration does not apply.

Mastering this section gives you the mechanistic framework for the entire pharmacology chapter that follows: drug interactions, adverse effects, and individualized dosing all flow from these physicochemical and metabolic principles.